EGFR and neoplasm: Although skin rash may be a pharmacodynamic marker of drug action (Albanell et al, 2002; Malik et al, 2003), its predictive value and potential as a surrogate marker for response to EGFR-targeted agents depends on the correlation of HER-kinase signaling in paired skin and tumour tissue which requires further investigation.